Consilium MedicumConsilium Medicum2075-17532542-2170Consilium Medicum9463110.26442/2075-1753_19.8.2.37-44Research ArticleComplex therapy of irritable bowel syndromeSimanenkovV. Ivisimanenkov@mail.ruSundukovaZ. Rzarina.sundukova@gmail.comSolovyevaO. I-I.I.Mechnikov North-West State Medical University of the Ministry of Health of the Russian Federation19082017198-2374428122021Copyright © 2017, Consilium Medicum2017The article presents modern view on the complex therapy of irritable bowel syndrome (IBS), which includes the use of miotropic spasmolytics, bulk laxatives, antimotility agents and psychotropic drugs. The features of pathogenetic treatment of patients with IBS. It is emphasized that the use of drugs correcting intestinal microflora - intestinal antiseptics, probiotics, prebiotics, including anti-inflammatory, regulating tone and motility of the gastrointestinal tract Iberogast®.irritable bowel syndromeRome IV criteriesintestinal antisepticsIberogastсиндром раздраженного кишечникаРимские критерии IVкишечные антисептикиИберогаст[Маев И.В., Черемушкин С.В., Кучерявый Ю.А. Синдром раздраженного кишечника. Римские критерии IV. О роли висцеральной гиперчувствительности и способах ее коррекции. Методическое пособие. М., 2016.][Шептулин А.А., Визе-Хрипунова М.А. Римские критерии синдрома раздраженного кишечника IV пересмотра: есть ли принципиальные изменения? Национальная школа гастроэнтерологов, гепатологов. Рос. журн. гастроэнтерологии, гепатологии, колопроктологии. 2016; 26 (5): 99-103.][Brandt L.J, Chey W.D, Foxx-Orenstein A.E. et al. An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol 2009; 104 (1): 1-35.][Lacy B.E., Mearin F.Тn, Lin Chang et al. Bowel Disorders. Gastroenterology 2016; 150: 1393-407.][Canavan C, West J, Card T. The epidemiology of irritable bowel syndrome. Clin Epidemiol 2014; 6: 71-80.][Chaudhary N.A, Trulove S.C. The irritable colon syndrome. A study of the clinical features, predisposing causes, and prognosis in 130 cases. Q J Med 1962; 31: 307-22.][Ford A.C, Forman D, Bailey A.G. et al. Irritable bowel syndrome: a 10-yr natural history of symptoms and factors that influence consultation behavior. Am J Gastroenterol 2008; 103: 1229-39.][Ford A.C et al. Systematic review and meta-analysis of the prevalence of irritable bowel syndrome in individuals with dyspepsia. Clin Gastroenterol Hepatol 2010; 8 (5): 401-9.][Halder S.L, Locke G.R., Schleck C.D. et al. Natural history of functional gastrointestinal disorders: a 12-year longitudinal population-based study. Gastroenterology 2007; 133: 799-807.][Irritable bowel syndrome. Br Med J 1972; 1 (5794): 197-8. Noauthorslisted.][Kim H.G. et al. G-Protein Beta3 Subunit C825T Polymorphism in Patients With Overlap Syndrome of Functional Dyspepsia and Irritable Bowel Syndrome. J Neurogastroenterol Motil 2012; 18 (2): 205-10.][Kruse F.H. Functional disorders of the colon: the spastic colon, the irritable colon, and mucous colitis. Cal West Med 1933; 39 (2): 97-103.][Longstreth G.F, Thompson W.G, Chey W.D.et al. Functional bowel disorders. Gastroenterology 2006; 130 (5): 1480-91.][Lovell R.M, Ford A.C. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol 2012; 10: 712-21.][Madisch A., Holtmann G., Plein K., Hotz J. Treatment of irritable bowel syndrome with herbal preparations: results of a double-blind, randomized, placebo-controlled, multicentre trial. Aliment Pharmacol Ther 2004; 19: 271-9.][Manning A.P, Thompson W.G, Heaton K.W, Morris A.F. Towards positive diagnosis of the irritable bowel. Br Med J 1978; 2 (6138): 653-4.][O'Donnell L.J.D, Virjee J., Heaton K.W. Detection of pseudodiarrhoea by simple clinical assessment of intestinal transit rate. Br Med J 1990; 300: 439-40.][Oliver Grudmannand Saunjoo L. Yoon Complementary and alternative medicines in irritable bowel syndrome: An integrative view. World J Gastroenterol 2014; 20 (2): 346-62.][Palsson O., Heymen S., Whitehead W.E. Abdominal pain versus abdominal discomfort: implications for diagnostic assessment of irritable bowel syndrome (IBS). United Eur Gastroenterol J 2014; 2: 405.][Rösch W., Vinson B., Sassin I. A randomised clinical trial comparing the efficacy of a herbal preparation STW 5 with the prokinetic drug cisapride in patients with dysmotility type of functional dyspepsia. Z Gastroenterol 2002; 40: 401-8.][Saito Y.A, Locke G.R, Talley N.J. et al. A comparison of the Rome and Manning criteria for case identification in epidemiological investigations of irritable bowel syndrome. Am J Gastroenterol 2000; 95 (10): 2816-24.][Simmen U., Kelber O, Okpanyi S.N. et al. Binding of STW 5 (Iberogast) and its components to intestinal 5-HT, muscarinic M3, and opioid receptors. Phytomedicine 2006; 13 (Suppl. 5): 51-5.][Thompson W.G, Longstreth G.F, Drossman D.A. et al. Functional bowel disorders and functional abdominal pain. Gut 1999; 45 (Suppl. 2): II43-II47.][Von Arnim U., Peitz U, Vinson B. et al. STW 5, a phytopharmacon for patients with functional dyspepsia: results of a multicenter, placebo-controlled double-blind study. Am J Gastroenterol 2007; 102: 1268-75.][Lacy B.E, Mearin F, Chang L et al. Bowel Disorders. Gastroenterology 2016; 150: 1393-407.][Camilleri M., Lasch K, Zhou W. Irritable bowel syndrome: Methods, mechanisms, and pathophysiology. The confluence of increased permeability, inflammation, and pain in irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol 2012; 303: 775-85.][Свистунов А.А., Осадчук М.А., Осадчук А.М., Буторова Л.И. Римские критерии синдрома раздраженного кишечника IV пересмотра (2016): что нового? Клиническая медицина][Батурова Л.И., Томилина Г.М. Синдром раздраженного кишечника: основные принципы диагностики и лечения в поликлинической практике. М.: Прима Принят, 2014.][Allam S. et al. Extracts from peppermint leaves, lemon balm leaves and inparticular angelica roots mimic the pro-secretory action of the herbal preparation STW5 in the human intestine. Phytomedicine 2015; 22: 1063-70.][Mohamed T. Khayyala et al. A multi-component herbal preparation, STW 5, shows anti-apoptoticeffects in radiation induced intestinal mucositis in rats. Phytomedicine 2014; 21: 1390-9.][Hames N, James K.C, Pugh W.K. Antifoaming and carminative actions of volantile oils. J Clin Pharmacy 1978; 2: 171-7.][Ulrich-Merzenich G, Shcherbakova A, Kelber O, Abdel-Aziz H. Multitargeting of STW 5 - the contribution of its components to the anti-inflammatory activity. Digestive Disease Week, Chicago 2017.][Koskinen K. Interaction between the herbal preparat on STW 5 and human intestinal bacteria in vitro. Digestive Disease Week, Chicago 2017.][Vinson B. Development of Iberogast: Clinical Evidence for Multicomponent Herbal Mixtures. In: Cooper R, Kronenberg F, editors. Botanical medicine: from bench to bedside. New Rochelle: Mary Ann Liebert, 2009; p. 167-89]